Table 4. Decline in systemic gp41-specific IgA in multiple cohorts.
| No. of subjects | |||
|---|---|---|---|
|
Cohort |
No. Samples per subjecta |
IgG+/IgA+b |
IgA↓c |
| Plasma donor | 4–29 | 14 | 6 |
| Trinidad | 8–17 | 7 | 6 |
| CHAVI 001 | 4–10 | 23 | 16 |
| Total | 44 | 28 | |
Abbreviation: Ig, immunoglobulin.
a
The number of longitudinal samples per subject analyzed over the course of acute infection are indicated.
b
The number of subjects with at least four time points that were tested that had detectable anti-gp41 IgG and IgA to measure decline are indicated.
c
Number of subjects with increasing/stable IgG and ≥2.5-fold decline in IgA from peak level.